18 August 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of lenvatinib mesylate and pembrolizumab in the NHS in England.

The combination.of lenvatinib mesylate and pembrolizumab is recommended as an option for adults with untreated advanced renal cell carcinoma only if:

• Their disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria and
• Nivolumab with ipilimumab would otherwise be offered and
• The companies provide lenvatinib mesylate and pembrolizumab according to the commercial arrangements

Read NICE Appraisal Consultation Document